In addition to improving ON time in patients with Parkinson disease, ND0612 was well tolerated, with only 6.3% of patients randomized to the treatment discontinuing the trial.
Ryan Case, PhD
Newly announced data from the phase 3 randomized, double-dummy BouNDless trial (NCT04006210) assessing NeuroDerm’s 24-hour/day subcutaneous infusion of liquid levodopa/carbidopa (LD/CD), met its primary end point of improvement in ON time among patients with Parkinson disease (PD).1
The drug, ND0612, is designed to improve the pharmacokinectic profiles of oral LD/CD by avoiding gastric involvement and maintaining stable and continuous therapeutic levodopa plasma concentrations. Over a 12-week treatment period, patients randomly assigned to the agent demonstrated a statistically superior difference of 1.72 hours in good ON time (P <.0001). Regulatory submissions for ND0612 in the US are expected to come this year and later in the European Union.
"With current, limited options for people with Parkinson’s disease experiencing motor fluctuations, ND0612 has the potential, subject to regulatory approval, to change the treatment paradigm and become an effective, well-tolerated treatment option to better control motor fluctuations," Ryan Case, PhD, head of Clinical Medical Affairs at Neuroderm, told NeurologyLive®. "This is because, while Levodopa is the standard of care therapy for Parkinson’s disease administered together with a levodopa degradation inhibitor (usually carbidopa), chronic oral levodopa therapy is often associated with the development of motor complications that result from fluctuating levodopa plasma concentrations (peaks and troughs), limiting its clinical utility."
ND0612 also demonstrated clinically meaningful results on the key secondary end point of OFF time (P <.0001), as well as other end points include the Movement Disorder Society (MDS)-Unified Parkinson’s Disease Rating Scale Part II score (P <.0001), the Patient Global Impression of Change (PGIC), and the Clinical Global Impression of Improvement (GCI-I)(P <.0001). In terms of safety, infusion site reactions such as hematoma, infection, and erythema, were more frequently reported in the ND0612 group compared with oral LD/CD, while ON and OFF phenomenon, falls were less frequently reported in the ND0612 group compared with oral LD/CD. Only 6.3% of patients randomly assigned to ND0612 during the double-blind period discontinued for any reason, including 5.5% due to AEs.
A population-based incident of Parkinson disease cases showed patients were more likely to develop PD dementia in 10 years with a lower level of lysosomal enzyme glucocerebrosidase activity.
"These results are meaningful to both patients and healthcare providers, as there will be a novel, minimally invasive, continuous subcutaneous LD/CD treatment option demonstrating encouraging efficacy and tolerability, thereby helping patients stay on treatment with better motor function – an important milestone leading to better health outcomes and less clinical burden for people with PD experiencing motor fluctuations," primary investigator Olivier Rascol, professor of clinical pharmacology, Toulouse University Hospital, said in a statement.1
Findings from BouNDless trial complemented long-term safety data from the BeyoND study (NCT02726386), which was published in early 2022. That open-label safety study included 214 patients with PD who were assigned to receive ND0612 for a regimen of either 16-hours/day or 24-hours/day. Of them, 120 completed the first year and 114 continued into the extension period, where they were followed for up to 102 months of treatment. Eligible patients were taking at least 4 levodopa doses/day, at least 1 other PD medication, and experienced at least 2 hours of OFF time/day with predictable morning OFF periods.2
As of May 2021, 64 patients were still in the study, with a treatment duration of up to 4.6 years. Infusion site reactions (ISR)/consent withdrawn due to ISR, found in 17.7% of patients, was the top reason for treatment discontinuation, followed by lack of efficacy (14.5%), and other treatment-emergent adverse events (TEAE; 12.1%). Overall, 73% of treated patients experienced at least 1 TEAE, with serious TEAEs occurring in 5.6% of patients. The most common systemic TEAEs were fall (16.4%), urinary tract infection (13.1%), and nausea (10.3%).
